PreModificationWarrantsMember
AwardType [Axis]
PostModificationWarrantsMember
ShareBasedCompensationWarrantsOneMember
Range [Axis]
ShareBasedCompensationWarrantsTwoMember
ShareBasedCompensationWarrantsFourMember
ShareBasedCompensationWarrantsFiveMember
ShareBasedCompensationWarrantsSixMember
ShareBasedCompensationWarrantsSevenMember
ShareBasedCompensationWarrantsEightMember
ShareBasedCompensationWarrantsNineMember
ShareBasedCompensationWarrantsElevenMember
February2012ConvertibleNotes12PercentMember
DebtInstrument [Axis]
InvestorRelationServicesMember
Equity Components [Axis]
InvestorRelationsAndPublicCompanyServicesMember
AdditionalInvestorRelationsServicesMember
WarrantModificationsMember
ForegoingExercisesMember
PlatinumMember
SeriesAPreferredStockMember
Statement Class Of Stock [Axis]
QualifiedFinancingMember
LegalEntityAxis
LegalEntity [Axis]
Pre-Modification [Member]
Short-term Debt, Type [Axis]
Post-Modification [Member]
CatoBioVentures [Member]
USNationalInstitutesOfHealth [Member]
Collaborative Arrangements and Non-collaborative Arrangements [Axis]
NIHGrantRevenueMember
DeferredRevenueArrangementType [Axis]
CatoResearchLtdMember
Senior Note1 [Member]
Related Party [Axis]
Senior Note 2 [Member]
Senior Note 3 [Member]
Senior Note 5 [Member]
SevenPercentNotesPayableAprilTwoThousandEleven [Member]
SevenPercentNotesPayableAugustTwoThousandTwelve [Member]
SevenPercentNotesPayable [Member]
CurrentPortion [Member]
SevenPercentNotesPayableNonCurrentPortion [Member]
BurrPilgerMayer [Member]
Desjardins [Member]
McCarthyTetrault [Member]
MayTwoThousandElevenMorrisonFoerster [Member]
AugustTwoThousandTwelveMorrisonAndFoersterNoteA [Member]
AugustTwoThousandTwelveMorrisonAndFoersterNoteB [Member]
NoteDiscountOne [Member]
SevenPointFivePercentNotesPayable [Member]
CurrentPortionOne [Member]
NonCurrentPortionAndDiscount [Member]
FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrent [Member]
TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayable [Member]
CurrentPortionTwo [Member]
NonCurrentPortion [Member]
TenPercentNotesPayableToUnrelatedParties [Member]
CurrentPortionThree [Member]
NonCurrentPortionAndDiscountOne [Member]
SevenPercentNotePayableToCatoHolding [Member]
NoteDiscountTwo [Member]
NotesPayableToRelatedParties [Member]
CurrentPortionFour [Member]
NonCurrentPortionAndDiscountTwo [Member]
IssuedToPlatinumOnTwoJulyTwoThousandTwelve [Member]
IssuedToPlatinumOnThirtyAugustTwoThousandTwelve [Member]
SeniorNotesNonCurrent [Member]
FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember
Note Discount [Member]
TwelvePercentConvertibleNotesNetNnonCurrent [Member]
Senior Note 4 [Member]
ShareBasedCompensationWarrantsMember
MaximumMember
ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLine [Axis]
MinimumMember
Preferred Stock
Series B Preferred Stock
Series B-1 Preferred Stock
Series C Preferred Stock
Common Stock
Additional Paid-In Capital
Treasury Stock
Notes Receivable from Sale of Stock
Deficit accumulated during the development stage
Fair Value, Inputs, Level 1 [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Put Opton Note Term Extension Liabilities [Member]
Warrant Liability [Member]
Exchange Warrant [Member]
Debt Instrument [Axis]
Oct 11 2012 Warrant [Member]
Oct 19 2012 Warrant [Member]
Feb 22 2013 Warrant [Member]
March 12 2013 Warrant [Member]
Exchange Note[Member]
Oct 11 2012 Note [Member]
Oct 19 2012 Note [Member]
Feb 22 2013 Note [Member]
March 12 2013 Note [Member]
PreModification PlatinumNote [Member]
PostModification PlatinumNote [Member]
ShareBasedCompensationWarrantsTenMember
ShareBasedCompensationWarrantsTwelveMember
Maximum [Member]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]
Minimum [Member]
ShareBasedCompensationWarrantsThirteenMember
ShareBasedCompensationWarrantsFourteenMember
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Unbilled contract payments receivable
Prepaid expenses
Total current assets
Property and equipment, net
Security deposits and other assets
Total assets
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable
Accrued expenses
Notes payable and accrued interest
Notes payable and accrued interest to related parties
Capital lease obligations
Deferred revenues
Total current liabilities.
Non-current liabilities:
Senior secured convertible promissory notes, net of discountof $1,963,100 at March 31, 2013 and accrued interest
Convertible promissory notes, net of discount of $499,300 at March 31, 2012 and accrued interest
Notes payable, net of discount of $1,142,600 at March 31, 2013 and $228,900 at March 31, 2012
Notes payable to related parties, net of discount of $147,200 at March 31, 2013 and $24,300 at March 31, 2012 and accrued interest
Warrant liability
Accrued officers' compensation
Capital lease obligations
Total non-current liabilities
Total liabilities
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 shares, including 500,000 Series A shares, authorized at March 31, 2013 and March 31, 2012; 500,000 and 437,055 Series A shares issued and outstanding at March 31, 2013 and March 31, 2012, respectively
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2013 and March 31, 2012; 23,480,169 and 18,704,267 shares issued at March 31, 2013 and March 31, 2012, respectively
Additional paid-in capital
Treasury stock, at cost, 2,713,308 and 2,083,858 shares of common stock held at March 31, 2013 and March 31, 2012, respectively
Notes receivable from sale of common stock
Deficit accumulated during development stage
Total stockholders' deficit
Total liabilities and stockholders' deficit
Senior secured convertible promissory notes, net of discount
Notes payable, net of discount
Notes payable to related parties, net of discount
Convertible promissory notes, net of discount
Stockholders deficit:
Preferred Stock, par value
Preferred Stock, Authorized
PreferredStockSeriesASharesIssued
PreferredStockSeriesASharesOutstanding
Common Stock, Par Value Par Share
Common Stock, Shares Authorized
Common Stock, Shares, Issued
Treasury Stock, Shares
Income Statement [Abstract]
Revenues:
Grant revenue
Collaboration revenue
Other
Total revenues
Operating expenses:
Research and development
Acquired in-process research and development
General and administrative
Total operating expenses
Loss from operations
Other expenses, net:
Interest expense, net
Change in put and note extension option and warrant liabilities
Loss on early extinguishment of debt
Other income
Loss before income taxes
Income taxes
Net loss
Deemed dividend on Series A Preferred stock
Net loss attributable to common stockholders
Basic and diluted net loss per common share
Weighted average shares used in computing basic and diluted net loss per common share
Comprehensive loss
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of imputed discount on non-interest bearing notes
Amortization of discounts on 7%, 7.5% and 10% notes
Amortization of discounts on Platinum notes
Amortization of discounts on August 2010 short-term notes
Amortization of discounts on February 2012 12% convertible notes
Loss on early extinguishment of debt
Loss on settlements of accounts payable
Change in warrant and put and note term extension option liabilities
Stock-based compensation
Expense related to modification of warrants
Fair value of Series C preferred stock, common stock, and warrants granted for services prior to the Merger
Fair value of common stock granted for services prior to the Merger
Fair value of common stock granted for services following the Merger
Fair value of warrants granted for services following the Merger
Fair value of additional warrants granted pursuant to exercises of modified warrants (fiscal year 2013) and under Discounted Warrant Exercise Program (fiscal year 2012)
Fair value of common stock issued for note term modification
Interest income on note receivable for stock purchase
Consulting services by related parties settled by issuing promissory notes
Gain on sale of assets
Changes in operating assets and liabilities:
Unbilled contract payments receivable
Prepaid expenses and other current assets
Security deposits and other assets
Accounts payable and accrued expenses
Deferred revenues
Net cash used in operating activities
Cash flows from investing activities:
Purchases of equipment, net
Net cash used in investing activities
Cash flows from financing activities:
Net proceeds from issuance of common stock and warrants, including units
Net proceeds from issuance of preferred stock and warrants
Proceeds from exercise of modified warrants (fiscal 2013) and under Discounted Warrant Exercise Program (fiscal 2012)
Proceeds from issuance of notes under line of credit
Proceeds from issuance of 7% note payable to founding stockholder
Net proceeds from issuance of 7% convertible notes
Net proceeds from issuance of 10% convertible notes and warrants
Net proceeds from issuance of Platinum notes and warrants
Net proceeds from issuance of 2008/2010 notes and warrants
Net proceeds from issuance of 2006/2007 notes and warrants
Proceeds from issuance of 7% notes payable
Net proceeds from issuance of August 2010 short-term notes and warrants
Net proceeds from issuance of February 2012 12% convertible notes and warrants
Repayment of capital lease obligations
Repayment of notes
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow activities:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of noncash activities:
Forgiveness of accrued compensation and accrued interest payable to officers transferred to equity
Exercise of warrants and options in exchange for debt cancellation
Settlement of accrued and prepaid interest by issuance of Series C Preferred Stock
Conversion of 10% notes payable, net of discount, and related accrued interest into Series C Preferred stock
Issuance of Series B-1 Preferred stock for acquired in-process research and development
Conversion of 7% notes payable, net of discount, and related accrued interest into Series B Preferred stock
Conversion of accounts payable into convertible promissory notes
Conversion of accounts payable into note payable
Conversion of accounts payable into common stock
Conversion of accrued interest on convertible promissory notes into common stock
Notes receivable from sale of common stock to related parties upon exercise of options and warrants
Capital lease obligations
Recognition of put option and note term extension option liabilities upon issuance of Platinum Notes
Incremental fair value of put option and note term extension option liabilities from debt modifications
Incremental fair value of note conversion option from debt modification
Incremental fair value of warrant from debt modifications
Recognition of warrant liability upon adoption of new accounting standard
Fair value of warrants issued with August 2010 short term notes
Note Discount upon issuance of August 2010 short-term notes
Fair value of warrants issued with February 2012 12% convertible notes
Note Discount upon issuance of February 2012 12% convertible notes
Conversion of 2006/2007 and 2008/2010 Notes into Units, including accrued interest of $1,365,600
Conversion of all series of pre-Merger preferred stock into Units
Conversion of 2011 Platinum Note into Series A Preferred stock, including accrued interest of $611,100 and conversion premium
Conversion of 7% note payable and accrued interest of $11,500 into common stock and warrants
Conversion of accounts payable to Morrison & Foerster, McCarthy Tetrault and Desjardins into notes payable
Accounts payable and cancellation premium converted into 2011 Private Placement Units
Accrued interest on Cato Holding Company note converted to note payable
Accounts payable settled in December 2011 and May/June 2012 warrant exercises
Insurance premiums settled by issuing note payable
Conversion of accrued interest and fees on February 2012 Notes into 2012 Private Placement Units
Accrued interest on July and August 2012 Notes to Platinum converted into Exchange Note
Accounts payable settled by issuance of stock or notes payable and stock
Accounts payable converted into 2012 Private Placement Units
Recognition of warrant liability upon issuance to Platinum of October 2012 Exchange Note and October 2012, February 2013 and March 2013 Investment Notes
Recognition of warrant liability for potential issuance to Platinum of Series A Exchange Warrant under the terms of the October 2012 Agreement
Statement [Table]
Statement [Line Items]
Beginning Balance, Amount
Beginning Balance, Shares
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $24,000, Amount
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $24,000, Shares
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $5,500, Amount
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $5,500, Shares
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $39,800, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $39,800, Shares
Issuance of Series B preferred stock at $5.545 per share for cash, net of issuance costs of $97,200, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, net of issuance costs of $97,200, Shares
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Shares
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $27,200, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $27,200, Shares
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount
Proceeds allocated to warrants issued in connection with Series C preferred stock, Shares
Issuance of Series C preferred stock at $6.00 per share for cash, net of issuance costs of $20,700, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, net of issuance costs of $20,700, Shares
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Shares
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Shares
Ending Balance, Amount
Ending Balance, Shares
Beginning Balance, Amount
Beginning Balance, Shares
Initial sale of common stock for cash to Founder, Amount
Initial sale of common stock for cash to Founder, Shares
Fair value of common stock issued for services, Amount
Fair value of common stock issued for services, Shares
Effect of the Merger, Amount
Effect of the Merger, Shares
Sale of common stock for cash, Amount
Sale of common stock for cash, Shares
Fair value of warrants issued for services
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares
Proceeds allocated to warrants issued in connection with 7% convertible notes
Proceeds allocated to warrants issued in connection with 10% convertible notes
Proceeds allocated to warrants issued in connection with Series C Preferred stock
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Cash, Amount
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Cash, Shares
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Debt cancellation, Amount
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Debt cancellation, Shares
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Notes receivable, Amount
Common stock issued upon exercise of options from 1999 Stock Incentive Plan and warrants for: Notes receivable, Shares
Share-based compensation expense
Forgiveness of accrued compensation and accrued interest payable to officers
Common stock issued upon settlement of employment contract, Amount
Common stock issued upon settlement of employment contract, Shares
Proceeds allocated to warrants issued in connection with Platinum Notes
Accrued interest on notes receivable
Common stock issued upon exercise of options from 2008 Stock Incentive Plan and Scientific Advisory Plan, Amount
Common stock issued upon exercise of options from 2008 Stock Incentive Plan and Scientific Advisory Plan, Shares
Proceeds allocated to warrants issued in connection with Platinum Notes and incremental fair value of warrant modification
Effect of reverse stock split
Cumulative effect of adopting new accounting standard
Common stock issued upon exercise of warrant, Amount
Common stock issued upon exercise of warrant, Shares
Common stock issued for cancellation of accounts payable and accrued interest, Amount
Common stock issued for cancellation of accounts payable and accrued interest, Shares
Incremental fair value of note conversion options from debt modification
Common stock issued for services, Amount
Common stock issued for services, Shares
Fair value of warrants issued for services and incremental fair value of warrant modification
Fair value of warrants issued in connection with 7.5% Notes
Fair value of warrants issued in connection with the August 2010 Short-Term Notes
Reclassification of warrant liability to equity
Incremental value of Platinum note modification
Incremental value of Morrison Foerster warrant modification
Stock issued in May 2011 Private Placement, net of $202,000 placement fees, Amount
Stock issued in May 2011 Private Placement, net of $202,000 placement fees, Shares
Payments on note receivable for sale of stock
Stock issued upon conversion of convertible promissory notes, Amount
Stock issued upon conversion of convertible promissory notes, Shares
Stock issued upon conversion of all series of preferred stock, Amount
Stock issued upon conversion of all series of preferred stock, Shares
Fair value of stock issued for services prior to the Merger, Amount
Fair value of stock issued for services prior to the Merger, Shares
Forgiveness of notes at the Merger, Amount
Forgiveness of notes at the Merger, Shares
Stock issued upon exercise of modified warrants (includes Platinum exercises), Amount
Stock issued upon exercise of modified warrants (includes Platinum exercises), Shares
Incremental value of warrant modifications (including modification of Platinum warrants)
Fair value of bonus warrants under Discounted Warrant Exercise Program
Stock issued in Fall 2011 Follow-on Offering, Amount
Stock issued in Fall 2011 Follow-on Offering, Shares
Stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount
Stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares
Fair value of stock issued for services following the Merger, Amount
Fair value of stock issued for services following the Merger, Shares
Placement fees on 12% Convertible Notes
Proceeds allocated to warrants issued and beneficial conversion feature in connection with 12% convertible notes
Stock issued in connection with note term extension, Amount
Stock issued in connection with note term extension, Shares
Stock issued upon conversion of Platinum Note to equity (net of Platinum warrant exercise reflected above), Amount
Stock issued upon conversion of Platinum Note to equity (net of Platinum warrant exercise reflected above), Shares
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Amount
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Shares
Common stock exchanged for Series A Preferred under agreements with Platinum: Note and Warrant Exchange Agreement, Amount
Common stock exchanged for Series A Preferred under agreements with Platinum: Note and Warrant Exchange Agreement, Shares
Fair value of warrants issued upon exercise of modified warrants
Fair value of shares issued in settlement of accounts payable, amount
Fair value of shares issued in settlement of accounts payable, shares
Modification of note receivable from sale of stock
Fair value of warrant issued to Cato Holding Company in connection with note payable restructure
Fair value of warrant issued to Cato Holding Company in connection with accounts payable restructure
Fair value of warrant issued to University Health Network in connection with accounts payable restructure
Fair value of warrants issued to Morrison & Foerster, Cato Reearch Ltd. and University Health Network in connection with accrued interest on underlying notes
Sale of Units in Winter 2012 Private Placement, net, Amount
Sale of Units in Winter 2012 Private Placement, net, Shares
Exchange of February 2012 convertible notes, Amount
Exchange of February 2012 convertible notes, Shares
Fair value of warrants issued to banker in connection with exchange of February 2012 convertible notes
Premium of fair value over face value of Exchange Note issued to PLatinum
Fair value of Series A Exchange Warrant issuable to Platinum recorded as a Warrant Liability
Proceeds allocated to beneficial conversion feature of Investment Notes issued to PLatinum in October 2012, February 2013 and March 2013
Incremental fair value of warrant modifications in Feburary 2013
Net Loss
Ending Balance, Amount
Ending Balance, Shares
Notes to Financial Statements
Description of Business
Basis of Presentation and Going Concern
Summary of Significant Accounting Policies
Fair Value Measurements
Property, Plant and Equipment [Abstract]
Property and Equipment
Business Combinations [Abstract]
AV-101 Acquisition
Accrued Expenses
Convertible Promissory Notes and Other Notes Payable
Capital Stock
Research and Development [Abstract]
Research and Development Expenses
Income Tax Disclosure [Abstract]
Income Taxes
Licensing and Collaborative Agreements
Text Block [Abstract]
Stock Option Plans and 401(k) Plan
Related Party Transactions
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies, Guarantees and Indemnifications
Subsequent Events
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information
Summary Of Significant Accounting Policies Policies
Basis of Presentation and Going Concern
Use of Estimates
Principles of Consolidation
Change in Authorized Number of Shares
Cash and Cash Equivalents
Property and Equipment
Impairment or Disposal of Long-Lived Assets
Revenue Recognition
Research and Development Expenses
Share-Based Compensation
Income Taxes
Concentrations of Credit Risk
Comprehensive Loss
Loss per Common Share
Recently Adopted Accounting Standards
Recent Accounting Pronouncements
Summary Of Significant Accounting Policies Tables
Earning Per Share
Fair Value Measurements Tables
Fair value heirarchy for liabilities measured at fair value on a recurring basis
Changes in Level 3 liabilities
Property and equipment
Accrued Expenses Tables
Accrued Expenses
Convertible Promissory Notes And Other Notes Payable Tables
Convertible Promissory Notes and Other Notes Payable
Exchange Warrant and Investment Warrants
Components of note discount and effective interest rate
Amended M&F Warrant
Capital Stock Tables
Black-Scholes Option Pricing Model
Black-Scholes Option Pricing Model on Modifications
Black-Scholes Option Pricing Model on Assumptions
Other Warrant Modifications assumptions
Black-Scholes Other Warrant Modifications Option Pricing Model on Assumptions
Warrants outstanding
Reserved Shares
Provision/benefit computed for income taxes
Components of deferred tax assets
Share-based compensation expense
Black-Scholes option valuation model assumptions for share-based compensation expense
Summary of stock option plan activity
Stock options outstanding and exercisable under Company's option plan
Assets under capital lease obligations
Future minimum payments required under Capital Leases
Future minimum principal payments related to Long-Term Debt
Subsequent Events Tables
Facility lease future minimum payments
Unaudited Quarterly Results of Operations
Description Of Business Details Textuals
Awarded by U.S. National Institutes
Outstanding shares acquired
Share repurchase
Shares outstanding at merger
Outstanding share representation
Number of shares authorized following amendment
Number of Preferred shares authorized following amendment
Series A Preferred Stock shares
Series A Preferred share par value
Conversion Rate, Series A Preferred shares
Conversion total, Series A Preferred to Common
Conversion to warrant, warrant value
Warrant exercise price
Basis Of Presentation And Going Concern Details Textuals
Accumulated Deficit during its development stage
Cash expenditure
Private placement proceeds
Summary Of Significant Accounting Policies Details
Loss per Common Share
Series A preferred stock issued and outstanding
Common stock warants issuable to Platinum upon exchange of Series A preferred stock under the terms of the October 11, 2012 Note Purchase and Exchange Agreement
Outstanding options under the 2008 and 1999 Stock Incentive Plans
Outstanding warrants to purchase common stock
10% convertible Exchange Note and Investment Notes issued to Platinum in October 2012, February 2013 and March 2013, including accrued interest through March 31, 2013 (2)
Total
Liabilities, Fair Value Disclosure
Warrant liability
Put option and note term extension option liabilities
Fair Value Measurements Details Textuals
Convertible promissory notes
Original Principle balance of notes
Repayment of debt in Percentage
Issued warrant to purchase common stock
Change in Fair value of the warrant liability
Increase in the put option and note term extension option liabilities
Remaining put option and note term extension option liabilities
Aggregated fair value of the warrants
Laboratory equipment
Computers and network equipment
Office furniture and equipment
Property and equipment gross
Accumulated depreciation and amortization
Av-101 Acquisition Details Textuals
Conversion feature
Series B-1 Shares issued
Series B-1 value per share
Pre-Merger purchase price
NIH awarded the Company aggregate support
Accrued Expenses Details
Accrued Expenses
Accrued professional services
Accrued research and development expenses
Accrued vacation pay and other compensation
Accrued placement agent fees
Accrued royalties and license fees
All other
Total
Principal Balance
Accrued Interest
Total
Exchange Warrant assumptions:
Market price of common stock
Exercise price
Risk-free interest rate
Volatility
Dividend rate
Fair value per share
Number of shares
Fair value at date of issuance
Components of discount and effective interest rate for Investment Notes
Face value
Discount attributable to fair value of warrant
Discount attributable to Beneficial conversion feature
Inception date carrying value
Effective Interest rate
Market price per share
Exercise price per share
Expected term (years)
Volatility
Fair Value per share
Schedule of Long-term Debt Instruments [Table]
Debt Instrument [Line Items]
Liability under the Registration Rights Agreement
July 2012 Platinum Note
August 2012 Platinum Note
July and August note Rate
Expected gross note proceeds
February 2012 Note
February Note rate
Warrant value
Aggregate share value
Registration rights agreement liability
October 2012 Platinum Note principal amount
October 2012 Platinum Note tranch amount
October 2012 Platinum Note gross proceeds
Private Placements
Private placement unit price
Financing required to sell Note
Legal Entity [Axis]
New unsecured promissory note
Shares Exercisable
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award Type [Axis]
Assumption:
Exercise price per share (weighted average)
Exercise price per share Upper
Risk-free interest rate Minimum
Risk-free interest rate Maximum
Expected term (years) Minimum
Expected term (years) Maximum
Volatility Minimum
Volatility Maximum
Dividend rate
Weighted Average Fair Value per share
Warrants option
Exercise Price
Expiration Date
Number of Warrants
Capital Stock Details 2
Upon exchange of all shares of Series A Preferred Stock currently issued and outstanding
Warrant shares issuable to Platinum upon exercise of common stock warrant upon exchange of Series A preferred stock under the terms of the October 11, 2012 Note Purchase and Exchange Agreement
110% of shares issuable upon conversion of 10% convertible Exchange Note and Investment Notes issued to Platinum in October 2012, February 2013 and March 2013, including interest accrued through maturity (2)
Pursuant to warrants to purchase common stock:
Subject to outstanding warrants
Issuable pursuant to accrued interest through maturity on outstanding promissory notes issued to Morrison & Foerster, Cato Research Ltd., and University Health Network
Pursuant to warrants to purchase common stock, total
Pursuant to stock incentive plans:
Subject to outstanding options under the 2008 and 1999 Stock Incentive Plans
Available for future grants
Pursuant to stock incentive plans, total
Upon sales of additional Units pursuant to the 2012 Private Placement of Units
Total
Class of Stock [Axis]
Purchase of common stock
Common stock, exercise price per share
Fair value of warrant
Market price per share
Common stock exercise price per share
Contractual term
Expected dividend rate
Common stock granted
Common stock granted value
Common stock granted date market price
Cash proceeds from common stock
Amounts due for services
Common stock purchse discription
Increased value of warrants exercised
common stock at a weighted average exercise price
Preferred stock issued
Common stock owned
Secured convertible promissory note
Convertible promissory note
Financing transactions gross proceeds
Investment in Qualified Financing
Amount of commitments from other investors
Period of commitments from other investors
Securities stated value per share
Authorized and outstanding shares
Research and development expenses
Income Taxes Details
Computed expected tax benefit
Losses not benefitted
Other
Income tax expense
Income Taxes Details 1
Net operating loss carry-forwards
Basis differences in fixed assets
Accruals and reserves
Total deferred tax assets, net
Valuation allowance
Net deferred tax asset
Valuation allowance increase
U.S. federal net operating loss carryforwards
state net operating loss carryforwards
Expected dividend yield
Exercise price
Market price on date of grant
Risk-free interest rate
Expected (years)
Volatility
Fair value per share at grant date
Number of Shares
Options outstanding at beginning of period
Options granted
Options exercised
Options cancelled
Options forfeited
Options expired
Options outstanding at end of period
Options exercisable at end of period
Weighted Average Exercise Price
Options outstanding at beginning of period
Options granted
Options exercised
Options cancelled
Options forfeited
Options expired
Options outstanding at end of period
Options exercisable at end of period
Weighted average grant-date fair value of options granted during the period
Total interest expense on note and the prior line of credit
Incurred expenses on research and subsequent other projects
CRL note interest expense
Commitments Contingencies Guarantees And Indemnifications Details
Capital lease obligations
Leased laboratory and computer equipment
Accumulated amortization
Leased laboratory and computer equipment, net
Commitments Contingencies Guarantees And Indemnifications Details 1
Future minimum payment, capital leases, Equipment
Lease payment 2014
Lease payment 2015
Lease payment 2016
Lease payment 2017
Lease payment 2018
Future minimum lease payments
Less imputed interest included in minimum lease payments
Present value of minimum lease payments
Less current portion
Non-current capital lease obligation
Commitments Contingencies Guarantees And Indemnifications Details 2
Future minimum payments, principal
2014
2015
2016
2017
2018
Thereafter through October 2023
Total
Future minimum payments under operating leases
Facility rent expense
Subsequent Events Details
Future minimum payment, operating lease
Lease payment 2014
Lease payment 2015
Lease payment 2016
Lease payment 2017
Lease payment 2018
Shares of common stock retroactively reflected as outstanding
Shares held by stockholders, pre-merger
Supplemental Financial Information Details
Total revenues
Total operating expenses
Loss from operations
Income taxes
Net loss
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Outstanding Options Under 2008 And 1999 Stock Incentive Plan And 1998 Scientific Advisory Board Plan.
Outstanding Warrants To Purchase Common Stock.
February 2012 12 Convertible Promissory Notes And Accrued Interest1.
Total.
Accrued Research And Development Expenses.
Accrued Placement Agent Fees.
Accrued Registration Rights Payments.
Pre Modification Warrants Member.
Post Modification Warrants Member.
Market Price Per Share.
Expected Term Years Maximum.
Weighted Average Fair Value Per Share.
Share Based Compensation Warrants One Member.
Share Based Compensation Warrants Two Member.
Share Based Compensation Warrants Four Member.
Share Based Compensation Warrants Five Member.
Share Based Compensation Warrants Six Member.
Share Based Compensation Warrants Seven Member.
Share Based Compensation Warrants Eight Member.
Share Based Compensation Warrants Nine Member.
Share Based Compensation Warrants Ten Member.
Share Based Compensation Warrants Eleven Member.
Share Based Compensation Warrants Twelve Member.
Exercise Price.
Convertible Promissory Notes And Other Notes Payable Table Text Block.
Blackscholes Option Pricing Model Table Text Block.
Awarded By U.S. National Institutes.
Outstanding Shares.
Original Principle Balance Of Notes.
Repayment Of Debt In Percentage.
Issued Warrant To Purchase Common Stock.
Change In Fair Value Of The Warrant Liability.
Increase In Put Option And Note Term Extension Option Liabilities.
Remaining Put Option And Note Term Extension Option Liabilities.
February 2012 Convertible Notes 12 Percent Member.
Desjardins Member.
Investor Relation Services Member.
Investor Relations And Public Company Services Member.
Additional Investor Relations Services Member.
Warrant Modifications Member.
Foregoing Exercises Member.
Platinum Member.
Qualified Financing Member.
Share Price1.
Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased1
Share Based Compensation Arrangement By ShareBased Payment Award Number Of Shares Available For Grant1.
Common Stock Value1.
Amounts Due For Services.
Common Stock Purchse Discription.
Increased Value Of Warrants Exercised.
Common Stock Owned.
Secured Convertible Promissory Note1.
Financing Transactions Gross Proceeds.
Investment In Qualified Financing.
Amount Of Commitments From Other Investors.
Cato Holding Company Member.
Contractual Term1.
Period Of Commitments From Other Investors2
Expiration Date.
Notes Payable Discount.
Notes Payable Discount Related Parties.
Convertible Notes Discount.
Exercise Price Per Share Weighted Avg.
Custom Element
Custom Element
Custom element.
Custom element.
Custom element.
Custom element.
Custom element.
Custom element.
Custom element.
Custom element.
Custom Element.
Custom element.
Custom element.
Custom element.
Custom element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom element.
Custom element.
Custom element.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Assets, Current
Assets
Liabilities, Current
Liabilities, Noncurrent
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities
LossOnEarlyExtinguishmentOfDebt
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Deposit Assets
Increase (Decrease) in Deferred Revenue
Net Cash Provided by (Used in) Operating Activities
Net Cash Provided by (Used in) Investing Activities
Repayments of Long-term Capital Lease Obligations
Repayments of Notes Payable
Net Cash Provided by (Used in) Financing Activities
Cash and Cash Equivalents, Period Increase (Decrease)
Capital Lease Obligations Incurred
StockholdersEquityForPreferredStock
SharesIssuedForPreferredStock
Shares, Issued
Basis of Accounting, Policy [Policy Text Block]
Property, Plant and Equipment, Policy [Policy Text Block]
Research and Development Expense, Policy [Policy Text Block]
Income Tax, Policy [Policy Text Block]
Schedule of Accrued Liabilities [Table Text Block]
ConvertiblePromissoryNotesAndOtherNotesPayableTableTextBlock
ScheduleofSharebasedCompensationExpenseTextBlock
Earnings Per Share [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Accrued Liabilities, Current [Abstract]
Long-term Debt, Gross
Fair Value Assumptions, Expected Volatility Rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Common Stock, Capital Shares Reserved for Future Issuance
EffectiveIncomeTaxRateReconciliationOther
Temporary Equity, Redemption Price Per Share
FairValueAssumptionsRiskFreeInterestRates
ShareBasedCompensationArrangementByShareBasedPaymentAwardVolatilityRate
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice2
Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Capital Lease Obligations [Abstract]
FutureMinimumPrincipalPayments
Operating Leases, Future Minimum Payments Due, Next Twelve Months
Operating Leases, Future Minimum Payments, Due in Two Years
Operating Leases, Future Minimum Payments, Due in Three Years
Operating Leases, Future Minimum Payments, Due in Four Years
Operating Leases, Future Minimum Payments, Due in Five Years